Skip to main content

The Daily Aggregate: Don’t Call It A Comeback

By November 16th, 2026General Articles2 min read

Just days after stepping down as CEO of Nvidia (NASDAQ: NVDA), Jensen Huang is reportedly considering a comeback.

The Financial Times reports that Huang has discussed returning to the company with close allies, some of whom are organizing a campaign to win support from Nvidia’s board and the White House. One ally reportedly wants to assemble a “war room” of Silicon Valley executives to push for his reinstatement.

Not everyone in Washington is on board.

Treasury Secretary Scott Bessent said Sunday that Nvidia needs a “dramatic shake-up” and should look outside the company for its next CEO. Nvidia’s board, meanwhile, said Friday it has not formally engaged any candidates and is still selecting a search firm.

All of this comes ahead of Nvidia’s earnings Tuesday after the close, its first report since Huang’s departure. Interim CEO Colette Kress will have plenty to answer for beyond the quarterly numbers.

Elsewhere, SpaceX (NASDAQ: SPCX) made history over the weekend, successfully catching its Starship spacecraft with the launch tower’s mechanical arms after nearly a day in orbit. The mission also delivered 26 Starlink satellites, although the Super Heavy booster failed its own recovery attempt and was lost.

Here is what else is moving under the radar this morning:

  • HubSpot (NYSE: HUBS) co-founder and returning CEO Brian Halligan purchased approximately $5 million worth of company stock, acquiring 22,985 shares shortly after returning to lead the company. A sizable insider purchase as HubSpot enters what Halligan has called its “refounding.”
  • Johnson & Johnson (NYSE: JNJ) announced plans to acquire Ollin Biosciences for $2.2 billion upfront, adding a late-stage experimental treatment for retinal diseases. Blackstone Life Sciences will provide $750 million to help fund Phase 3 development.
  • Summit Therapeutics (NASDAQ: SMMT) received an FDA Complete Response Letter for its lung cancer treatment ivonescimab. Regulators determined the company had not established sufficient evidence of effectiveness without a statistically significant overall survival benefit, preventing approval in its current form.

STN Desk Takeaway: Nvidia’s leadership crisis isn’t going away, and now there’s a fight over who should run the company. With earnings tomorrow, investors have to weigh the company’s business against a very public battle over its future. 

Leave a Reply